<DOC>
	<DOC>NCT02122809</DOC>
	<brief_summary>The purpose of this dose-escalation study is to assess the safety and tolerability of treatment with Chiauranib administered orally over a range of doses in patients with advanced solid tumors.</brief_summary>
	<brief_title>Phase I Study of Chiauranib in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The purpose of this study is to assess the tolerability and safety include adverse events, vital signs, laboratory tests ,etc., of a range of doses of Chiauranib in solid tumor patients, and to determine the dose limit toxicity and the maximum tolerable dose.</detailed_description>
	<criteria>1. Histological or cytological confirmation of advanced solid tumor, including nonsmall cell lung cancer, colorectal cancer, ovarian cancer, renal cell carcinoma, gastrointestinal stromal tumor, gastric cancer, et al; 2. Patients with advanced solid tumors refractory to standard therapy or for which no standard therapy exists; 3. Body mass index (BMI) is between 18 and 28; 4. Age: 18~65 years; 5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1; 6. Laboratory criteria are as follows: 1. Complete blood count: hemoglobin (Hb) ≥100g/L (no blood transfusion within 14 days); absolute neutrophil count (ANC) ≥1.5×109/L ; platelets &gt;=100×109/L 2. Biochemistry test: serum creatinine &lt;=1.5×upper limit of normal (ULN); total bilirubin≦1.5×ULN; alanine aminotransferase / aspartate aminotransferase≦1.5×ULN; fasting triglyceride (TG) &lt;= 3.0 mmol/L; total cholesterol &lt;= 7.75 mmol/L 3. Coagulation test: International Normalized Ratio (INR) &lt; 1.5 7. Women of childbearing potential should be nonlactating patients, and must agree to use effective contraceptive methods prior to study entry, during study participation, and up to 6 months following completion of therapy. A serum or urine pregnancy test within 7 days before enrollment must be negative; Men must agree to use effective contraceptive methods during study participation and up to 6 months following completion of therapy; 8. Willingness to sign a written informed consent document 1. Life expectation &lt; 3 months; 2. Subjects received anticancer therapy (including chemotherapy, radiotherapy, targeted therapy and endocrine therapy, et al) within 4 weeks prior to study entry; Subjects received nitrosoureas or mitomycin chemotherapy within 6 weeks prior to study entry; 3. Have uncontrolled or significant cardiovascular disease, including: 1. Myocardial infarction (&lt; the last 12 months) 2. Uncontrolled angina (&lt; the last 6 months) 3. Congestive heart failure (&lt; the last 6 months), or Left Ventricular Ejection Fraction (LVEF) &lt; 50% prior to study entry 4. History of any significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or TdP) 5. History of significant QT interval prolongation, or Corrected QT Interval (QTc) &gt; 450 ms prior to study entry 6. History of cerebrovascular accident 7. Symptomatic coronary heart disease requiring treatment with agents 8. Uncontrolled hypertension (&gt; 140/90 mmHg) by single agent; 4. Have active bleeding , current thrombotic disease, or patients with bleeding potential receiving anticoagulation therapy; 5. History of deep vein thrombosis or pulmonary embolism; 6. Have unsolved toxicities (&gt; grade 1) from prior anticancer therapy; 7. Have clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, that would impair the ingestion,transportation or absorption of oral agents, or patients undergone gastrectomy; 8. Have symptomatic brain metastasis; 9. History of organ transplantation; 10. Proteinuria positive; 11. Congenital or acquired immunodeficiency, active infections; 12. Any mental or cognitive disorder, that would impair the ability to understand the informed consent document or the operation and compliance of study; 13. Any other condition which is inappropriate for the study in the opinion of the investigators.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chiauranib, advanced solid tumors, phase 1 study</keyword>
</DOC>